Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 6/20 | 1.00 |
| ▸ | IKBKB | O14920 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.59 |
| ▸ | CHUK | O15111 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | OGG1 | O15527 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919937 | 0.85 | LIMK1 (0.73) | LIMK1IKBKBKDM4EALDH1A1ALOX15 | |
| SCHEMBL15766514 | 0.83 | LIMK1 (0.71) | LIMK1IKBKBKDM4EALDH1A1ALOX15 | |
| SCHEMBL11074064 | 0.81 | LIMK1 (0.68) | LIMK1IKBKBKDM4EALDH1A1ALOX15 | |
| SCHEMBL649968 | 0.81 | LIMK1 (0.68) | LIMK1IKBKBKDM4EALDH1A1ALOX15 | |
| SCHEMBL16581218 | 0.80 | GABRA1 (0.77) | LIMK1IKBKBKDM4EALDH1A1ALOX15 | |
| SCHEMBL29285354 | 0.80 | OGG1 (0.69) | LIMK1IKBKBKDM4EALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL9432204 | 0.79 | LIMK1 (0.66) | LIMK1IKBKBKDM4EALDH1A1ALOX15 | |
| SCHEMBL7675240 | 0.79 | MCL1 (0.71) | LIMK1IKBKBKDM4EALDH1A1MEN1 | |
| SCHEMBL347996 | 0.79 | LIMK1 (0.66) | LIMK1IKBKBKDM4EALDH1A1ALOX15 | |
| SCHEMBL29483598 | 0.79 | LIMK1 (0.68) | LIMK1IKBKBKDM4EALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307513-A | 3-Aminobenzo [ b ] thiophene compound and preparation method and application thereof | 河南工业大学 | 2024-07-09 | — | — | CN | claimed |
| EP-1444010-A2 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | claimed |
| WO-2003037886-A2 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-05-08 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-118307513-A | 3-Aminobenzo [ b ] thiophene compound and preparation method and application thereof | 河南工业大学 | 2024-07-09 | — | — | CN | disclosed |
| US-9707210-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707210-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160030390-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | Board of Regents of the Nevada System of Higher Ed ucation on behalf of the University of Nevada Ren (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160030390-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | Board of Regents of the Nevada System of Higher Ed ucation on behalf of the University of Nevada Ren (US) | 2016-02-04 | — | — | US | disclosed |
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1444010-A2 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003037886-A2 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030390-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | LIMK1 2306/4885IKBKB 2176/4885KDM4E 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.